Posted by Michael Wonder on 17 Oct 2017
Anika announces regulatory approval for Monovisc in Australia for the treatment of pain associated with osteoarthritis of all synovial joints
16 October 2017 - Anika Therapeutics today announced that regulatory authorities in Australia granted approval to Monovisc, Anika's single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee.
Monovisc is commercially available in over twenty countries, including the United States, Canada, and various European countries. Monovisc also recently received approval in the Asia-Pacific countries of India and Taiwan.
Anika intends to further expand Monovisc into additional international markets in 2018.
